Stock Titan Trading tools for traders and investors.

-

02:38:46 AM

Last HOTH Stock Market News

HOTH - Hoth Therapeutics Inc

03/01/21 3:02 PM

Nasdaq : HOTH

Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as

RHEA-AI

neutral

02/26/21 11:05 AM

Nasdaq : HOTH

Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its licensing agreement from North Carolina State University (" NC State") to include the worldwide development and commercialization of treatments targeting

RHEA-AI

neutral

02/25/21 9:55 AM

Nasdaq : HOTH

Hoth Therapeutics Retains RedChip to Increase Investor Awareness

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it retained RedChip Companies, Inc. ("RedChip") to lead its investor relations efforts.RedChip is the leader in investor relations, financial media, and research for

RHEA-AI

neutral

02/24/21 10:20 AM

Nasdaq : HOTH

Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has filed a provisional patent application with the United States Patent and Trademark Office for the use of one of its current portfolio therapeutics to treat and prevent

RHEA-AI

neutral

02/23/21 8:02 AM

Nasdaq : HOTH

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for their HT-001 product. The

RHEA-AI

neutral

02/18/21 8:01 AM

Nasdaq : HOTH

Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to expand the development of the HT-003 active pharmaceutical ingredient (API) to pursue a new indication for the treatment of inflammatory bowel diseases

RHEA-AI

neutral

02/17/21 8:00 AM

Nasdaq : HOTH

Hoth Therapeutics to Present at the Diamond Equity Research Emerging Growth Invitational 2021 Virtual Conference

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it will be presenting at the upcoming the Diamond Equity Research Growth Invitational virtual investor conference on February 24, 2021.Hoth Therapeutics is scheduled

RHEA-AI

neutral

02/10/21 1:30 PM

Nasdaq : HOTH

Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member, Michael Peter, Ph.D., published a whitepaper in bioRxiv regarding COVID-19 SARS-CoV-2 titled,"Transformations, Comparisons, Analysis of

RHEA-AI

neutral

02/08/21 2:52 PM

Nasdaq : HOTH

Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed an agreement with Camargo Pharmaceutical Services to facilitate the writing and submission of the Investigational New Drug application for HT-001 topical

RHEA-AI

neutral

02/02/21 8:45 AM

Nasdaq : HOTH

Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipeline of novel therapeutics targeting dermatological, COVID-19 and support care indications.Drug Pipeline Highlights:BioLexa

RHEA-AI

positive